Amgen/Takeda VEGF Inhibitor Motesanib Faces Setback In NSCLC
This article was originally published in The Pink Sheet Daily
Executive Summary
Enrollment in a Phase III trial in NSCLC patients is suspended after early mortality rates were seen in the treatment arm.
You may also be interested in...
Amgen/Takeda To Re-start Motesanib Lung Cancer Trial
Amgen and partner Takeda are getting set to re-start a Phase III trial of the vascular endothelial growth factor inhibitor motesanib in non-small cell lung cancer, after a conditional go-ahead from an independent data monitoring committee
Amgen/Takeda To Re-start Motesanib Lung Cancer Trial
Amgen and partner Takeda are getting set to re-start a Phase III trial of the vascular endothelial growth factor inhibitor motesanib in non-small cell lung cancer, after a conditional go-ahead from an independent data monitoring committee
Motesanib Gets Green Light In Lung Cancer Trial
Amgen/Takeda now altering Phase III design for a smaller patient pool.